RADBIO

RADBIO is a biopharmaceutical startup focusing on developing a therapeutic platform targeting TGF-beta, known as the "master regulator of fibrosis." Fibrosis, a significant factor in the cause of death for many diseases, lacks effective treatments to halt or reverse its progression, despite existing drugs that can delay it. RADBIO's innovative approach revolves around TGF-β, recognized as the primary driver of fibrosis. The company has made a breakthrough by identifying a new human protein, a unique soluble splice variant of the TGF-beta receptor 2, and is using genetic engineering to develop new assets. This enables them to tailor assets and delivery strategies according to specific indications, extending the potential applications and minimizing risk while enhancing value. Founded in 2018 and headquartered in the United States, RADBIO operates at the intersection of biopharma, biotechnology, healthcare, and pharmaceuticals. Currently, there is no information available regarding the last investment and associated investors.